IP Verse

Bayer Pharma Ag V. Lupin Limited - 1:25-cv-00349

Bayer Pharma Ag V. Lupin Limited (Case No. 1:25-cv-00349), filed on Mar 20, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-00349
Filing Date
Mar 20, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Bayer Pharma AG -
Lupin Pharmaceuticals, Inc. -
Janssen Pharmaceuticals, Inc. -

Patents Involved

There is a single patent involved in this case.

Application NumberPatent Number
-US10828310B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Mar 20, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025COMPLAINT for ANDA/PATENT INFRINGEMENT filed with Jury Demand against Lupin Limited, Lupin Pharmaceuticals, Inc. ( Filing fee $ 405, receipt number ADEDC-4641999.) - filed by Bayer Pharma AG, Bayer AG, Janssen Pharmaceuticals, Inc. (Attachments: # 1 Exhibit A - E, # 2 Civil Cover Sheet)(cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025Summons Issued as to Lupin Limited on 3/20/2025; Lupin Pharmaceuticals, Inc. on 3/20/2025. (Attachments: # 1 Summons Issued)(cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG, Bayer Pharma AG. (cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (cdd) (Entered: 03/20/2025)PACER Document
Mar 20, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/22/2023. Date of Expiration of Patent: (See Form). (cdd) (Entered: 03/20/2025)PACER Document